Oman Investment Authority (OIA) has announced that its subsidiary, National Pharmaceutical Industries Company (NPI), has received the prestigious United States Food and Drug Administration (USFDA) certification.
Chairman of NPI, Dr Waleed al Zadjali, shared the following in a statement: "Over the past few years, NPI has been expanding its production capacities, adding new product offerings, developing newer markets, and constantly upgrading its quality management system and partnering with various multinationals. This USFDA approval is a result of the overall strategic thrust of the company.” The certification, which was received in January this year, will allow the company, which currently holds a portfolio of over 150 medications, to enter the US market, in addition to positioning the Sultanate of Oman as a “world-class, reliable drug manufacturer and supplier”.
The company has previously received the European Union’s Good Manufacturing Practice accreditation from the Europe Medicinal Authority and product approvals from the United Kingdom’s Medicines and Healthcare products Regulatory Agency.
The company's products are currently sold in over 60 countries worldwide.
NPI was first established in 2002. It currently operates four plants, two in the Rusayl industrial City in Oman, one in the United Arab Emirates and another in the Kingdom of Saudi Arabia.
The company has an annual production capacity of 1.5 billion tablets, 100 million pill boxes, 20 million syrups and 400 million capsules.
Oman Observer is now on the WhatsApp channel. Click here
